Regulatory-First Scale in High-Risk Markets

Client Profile

Mid-market men's wellness brand with existing DTC revenue, interested in THC integration post–Schedule III. High concern around FDA enforcement and investor optics.

Challenge

The client wanted to add THC to its flagship product line quickly after Schedule III reclassification, believing federal risk had been eliminated. Their original plan would have invalidated their dietary supplement status, exposed them to FDA enforcement, and collapsed national distribution. They needed speed without contamination.

AskBuc Solution

• Designed a structurally separated, dual-lane commercialization model
• Lane A (Nationwide): Retained full FDA dietary supplement compliance, reformulated for performance, circulation, and stress resilience, manufactured via cGMP partner
• Lane B (State-Legal THC): Low-dose THC formulation (1–5mg), separate manufacturing, labeling, and distribution, dispensary-only sales within compliant states
• Provided formulation oversight with in-house chemists, compliance architecture, and launch sequencing to avoid regulatory overlap

Client Profile

Cannabis-adjacent startup with strong branding but weak backend. No compliant manufacturer secured. Outsourced formulation with no ownership.

Challenge

The client could not scale past pilot batches because their manufacturer lacked full FDA cGMP alignment, formulation IP was externally owned, and each iteration required weeks of renegotiation. They needed immediate operational control and access to massive scale manufacturing.

AskBuc Solution

• Integrated the client into our existing fully FDA-compliant manufacturing stack with massive scale capacity
• Transitioned formulation oversight in-house with owned materials and proprietary processes
• Migrated formulas into compliant documentation with full IP ownership transfer
• Stabilized active ingredient sourcing through our controlled supply chain
• Improved bioavailability and shelf stability through our in-house chemistry team
• Locked repeatable batch specifications for consistent scale production

Client Profile

Early-stage wellness brand with aggressive growth targets, planning interstate THC ecommerce.

Challenge

The client believed Schedule III allowed THC in supplements and direct-to-consumer national shipping. This would have triggered immediate FDA and DEA risk, potentially destroying the company before launch.

AskBuc Solution

• Halted the launch and rebuilt the strategy from compliance-first principles
• Removed THC from nationwide SKUs to preserve FDA dietary supplement status
• Repositioned cannabis formulations as state-regulated products with proper licensing
• Implemented compliant language (no disease or sexual performance claims)
• Created a phased roadmap for future IND optionality leveraging our manufacturing infrastructure

Client Profile

Industry reference based on public market parallels and our operational model.

Challenge

Brands like Charlotte's Web scaled nationally by avoiding THC in supplements, maintaining FDA-conscious positioning, and investing early in compliant manufacturing and testing. While many competitors were wiped out by enforcement, compliance-first brands survived, scaled, and attracted institutional capital.

AskBuc Solution

• AskBuc applies this same discipline to the post–Schedule III era
• Massive scale manufacturing capacity with owned materials eliminates dependency on third parties
• Vertical integration from formulation chemistry to finished goods production
• Controlled supply chain with proprietary ingredient sourcing
• Built for enforcement reality and future FDA optionality